November 18, 2022 New Mexico Department of Health issued a HAN recommending against the use of Bebtelovimab as treatment for COVID-19 due to the high proportion of resistant variants. There are currently no authorized monoclonal antibody treatments for COVID-19 at this time. Remdesivir, Paxlovid, and Molnupiravir remain effective treatments against currently circulating variants and emerging variants.

Please note that currently no facilities in New Mexico are offering outpatient Remdesivir. If your facility is offering outpatient Remdesivir, please contact COVID.Therapeutics@state.nm.us so that we may update our provider information.